Table 5. Summary of Magnetic Resonance Imaging (MRI) Screening Studies in Women at Hereditary Risk of Breast Cancer
| Series | Rijnsburger [296] | Warner [291] | MARIBS [290] | Kuhl [294] | Weinstein [297] | Sardanelli [298] | Totals | |
| N Patients | Overall | 2,157 | 236 | 649 | 687 | 609 | 501 | 4,839 |
| BRCA1/BRCA2 Carriers | 594 | 236 | 120 | 65 | 44 | 330 | 1,389 | |
| N Screening Episodes | 6,253 | 457 | 1,881 | 1,679 | 1,592 | 11,862 | ||
| N Cancers | Baseline | 22a | 13 | 20 | 10 | 0 | 0 | 65 |
| Subsequent | 97 | 9 | 15 | 17 | 18 | 52 | 208 | |
| Invasiveb | 78 | 16 | 29 | 8 | 11 | 44 | 186 | |
| In situ | 19 | 9 | 6 | 9 | 7 | 8 | 58 | |
| Annual Incidence | 10.4/1,000 | 19/1,000 | ||||||
| Detected at Planned Screening | 78 | 21 | 33 | 27 | 18 | 49 | 226 (83%) | |
| N Detected by Each Modality | Mammography | 31c | 8 | 14 | 9 | 7 | 25 | 94 (42%) |
| MRI | 51c | 17 | 27 | 25 | 12 | 42 | 174 (77%) | |
| Ultrasoundd | 7 | 10 | 3 | 26 | 46 (41%) | |||
| Follow-up | Median of 4.9 y | Minimum of 1 y | 2–7 y | Median of 29.09 mo | 2 y | 3 y | ||
| aBased upon the first 1,909 women screened.[288] | ||||||
| bIncludes patients with invasive cancer only and patients with both invasive and in situ cancers. | ||||||
| cIncludes only 75 cancers detected in women who underwent both mammographic and MRI screening. | ||||||
| dRestricted to studies in which ultrasound was performed. |
References
- Kriege M, Brekelmans CT, Boetes C, et al.: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351 (5): 427-37, 2004. [PUBMED Abstract]
- Leach MO, Boggis CR, Dixon AK, et al.: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365 (9473): 1769-78, 2005 May 21-27. [PUBMED Abstract]
- Warner E, Plewes DB, Hill KA, et al.: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292 (11): 1317-25, 2004. [PUBMED Abstract]
- Kuhl C, Weigel S, Schrading S, et al.: Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 28 (9): 1450-7, 2010. [PUBMED Abstract]
- Rijnsburger AJ, Obdeijn IM, Kaas R, et al.: BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 28 (36): 5265-73, 2010. [PUBMED Abstract]
- Weinstein SP, Localio AR, Conant EF, et al.: Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol 27 (36): 6124-8, 2009. [PUBMED Abstract]
- Sardanelli F, Podo F, Santoro F, et al.: Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. Invest Radiol 46 (2): 94-105, 2011. [PUBMED Abstract]
